BrainsWay (NASDAQ:BWAY - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.05, Zacks reports. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%.
BrainsWay Stock Performance
NASDAQ:BWAY opened at $9.19 on Tuesday. BrainsWay has a 52 week low of $4.61 and a 52 week high of $11.79. The firm has a market cap of $173.02 million, a price-to-earnings ratio of 91.91 and a beta of 1.29. The firm's 50-day simple moving average is $10.21 and its 200 day simple moving average is $9.57.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of BrainsWay in a research report on Monday, December 23rd.
Check Out Our Latest Stock Analysis on BrainsWay
BrainsWay Company Profile
(
Get Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BrainsWay, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BrainsWay wasn't on the list.
While BrainsWay currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
